Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression

Affiliations

• ¹ University Grenoble Alpes, Department of Hepato-Gastroenterology and Digestive Oncology, CHU Grenoble Alpes, Institute for Advanced Biosciences INSERM U1209, Grenoble, France. tdecaens@chu-grenoble.fr.
• ² Medical Oncology, Policlinico Universitario A. Gemelli, Roma, Italy.
• ³ Medical Oncology, CHU Saint Eloi, Montpellier, France.
• ⁴ NCT/UCC Early Clinical Trial Unit, University Hospital Carl-Gustav-Carus, Dresden, Germany.
• ⁵ Oncology, IRCCS San Raffaele, Milan, Italy.
• ⁶ Service d'Hépato-Gastro-Entérologie, Hôpital de la Croix Rousse, Lyon, France.
• ⁷ Service d'Hépato-Gastroentérologie et d'Oncologie Digestive, Groupe Hospitalier Haut-Lévêque, CHU Bordeaux, Pessac, France.
• ⁸ Service Hépatologie, Hôpital Jean-Verdier, Bondy, France.
• ⁹ Reparto di Gastroenterologia ed Endoscopia Digestiva, Ospedale Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy.
• ¹⁰ Division of Gastroenterology Policlinico di Modena, Modena, Italy.
• ¹¹ Gastrointestinal Oncology, Goethe University Hospital, Frankfurt, Germany.
• ¹² Clinical Biomarker & Companion Diagnostics, Merck KGaA, Darmstadt, Germany.
• ¹³ Biostatistics, Merck KGaA, Darmstadt, Germany.
• ¹⁴ Global Patient Safety Innovation, Merck KGaA, Darmstadt, Germany.
• ¹⁵ Global Clinical Development Oncology, Merck KGaA, Darmstadt, Germany.
• ¹⁶ Medical Oncology, Paris-St Joseph Hospital, Paris, France.
• ¹⁷ Medical Oncology, Saint-Louis Hospital & Paris 7 University, Paris, France.